Loading
A phase 1/2 trial of Rocapuldencel-T run by Argos Therapeutics, completed.
Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer is a phase 1/2 interventional study registered as NCT00272649 by Argos Therapeutics, with 22 participants enrolled, started 2006-01. Conditions recorded: Renal Cell Carcinoma. Interventions recorded: AGS-003.
Shares Rocapuldencel-T, Argos Therapeutics, Renal cell carcinoma and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics, Renal cell carcinoma and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics, Renal cell carcinoma and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics, Renal cell carcinoma and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/